JNJ
Johnson & Johnson
Pharmaceuticals, medical devices, consumer health products. Track real-time insider trading activity, SEC Form 4 filings, and executive stock transactions.
Insider Buys
8
$45.86M
Insider Sales
7
$32.48M
Total Volume
$78.34M
15 transactions
Net Activity
+$13.38M
Net buying
Sentiment Rating
Strong AccumulationCEO Conviction Index
High Conviction Accumulation
Key Drivers
- •Moderate accumulation: purchases represent 59% of total transaction value.
- •Cluster buying: 5 unique insiders purchased shares, showing strong alignment.
- •CEO buying activity detected. When chief executives put their own money at risk, it is historically a strong bullish signal.
- •CFO buying activity detected. Statistical studies show CFO purchases have high predictive power due to their direct visibility into balance sheet details.
- •Ultra-high accumulation: total purchase value exceeds $10M.
- •Significant liquidation: total sale value exceeds $10M.
Score Methodology
The Insider Confidence Score (1-100) measures executive conviction. Starting from a neutral 50, it adjusts based on:
- +15Strong Buy Ratio: Purchases > 70% of volume (or up to -15 for heavy sales).
- +20Cluster Buying: ≥3 unique insiders buying within a 30-day window.
- +15CEO Buying: CEO committing own capital shows high conviction.
- +10CFO Buying: CFO purchasing shares shows financial alignment.
Joseph Wolk
CFO
$19.80M total
Chief Operating Officer
COO
$18.40M total
VP Operations
VP
$17.57M total
Joaquin Duato
CEO
$12.29M total
Board Director
Dir
$10.27M total
Over the last 90 days, corporate insiders at Johnson & Johnson (JNJ) engaged in a total of 15 transactions reported via SEC Form 4 filings. Among these, 8 were open-market purchases and 7 were sales. The total volume of insider trading reached $78.34M.
The net insider activity for JNJ shows a net buying bias of $13.38M. This activity represents a 59% buy ratio, suggesting that insiders are currently neutral on the company's near-term outlook relative to recent history.
The most notable individual transaction was a Purchase by Joseph Wolk (CFO), who traded 43.0K shares valued at $9.26M on Sep 12, 2026.
Quick Actions
Explore Peers in Drug Manufacturers
Compare insider activity and sentiment scores across similar organizations.
FAQs About Johnson & Johnson Insider Trading
Answers to common questions regarding corporate filings and executive sentiment for JNJ.